![Anavex Life Sciences Corp. logo](/logos/AVXL.webp)
Anavex Life Sciences Corp.
NASDAQ:AVXL
Overview | Financials
Company Name | Anavex Life Sciences Corp. |
Symbol | AVXL |
Currency | USD |
Price | 5.15 |
Market Cap | 436,696,825 |
Dividend Yield | 0% |
52-week-range | 3.25 - 10.45 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Christopher U. Missling M.B.A., M.S., Ph.D. |
Website | https://www.anavex.com |
An error occurred while fetching data.
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD